Lineage Cell Therapeutics

LCTXPhase 2

Carlsbad, United StatesFounded 1990lineagecell.com

Lineage Cell Therapeutics is a clinical-stage biotech focused on developing novel allogeneic cell therapies for serious unmet medical needs. Its core technology, the AlloSCOPE™ platform, enables the scalable and consistent production of specialized human cells from pluripotent cell lines. The company is advancing multiple programs, including OPC1 for spinal cord injury and OpRegen for geographic atrophy, and has established a significant collaboration with Genentech. Lineage is publicly traded on the NYSE American under the ticker LCTX.

Market Cap

$361.2M

Founded

1990

Focus

BiologicsDiagnostics

LCTX · Stock Price

USD 1.450.03 (-2.03%)

Historical price data

AI Company Overview

Technology Platform

AlloSCOPE™ (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering) platform for the directed differentiation of pluripotent cell lines into specialized, transplantable human cell types.

Pipeline Snapshot

3 drugs in pipeline

Drug	Indication	Stage
AST-OPC1	Cervical Spinal Cord Injury	Phase 1/2
OPC1	Spinal Cord Injury Cervical	Phase 1
GRNOPC1	Spinal Cord Injury	Phase 1

Funding History

Total raised: $26M

PIPE$16MUndisclosedDec 15, 2021

PIPE$10MUndisclosedMay 15, 2020

Opportunities

The primary growth opportunities lie in successfully advancing its clinical pipeline, particularly OpRegen in the large geographic atrophy market and OPC1 for spinal cord injury.

The Genentech collaboration provides significant validation and resources to expand into broader ocular indications.

The platform's ability to generate multiple cell types allows for potential expansion into new therapeutic areas.

Risk Factors

Key risks include clinical trial failures, regulatory hurdles specific to complex cell therapies, intense competition in target markets, and the ongoing need to raise substantial capital to fund operations and development.

Manufacturing scalability for allogeneic cell products also presents a technical and operational challenge.

Competitive Landscape

Lineage faces competition from pharmaceutical companies with approved drugs for geographic atrophy (e.g., Apellis, Iveric Bio), other biotechs developing cell therapies for spinal cord injury and hearing loss, and numerous oncology immunotherapy developers. Its differentiation is its proprietary, scalable allogeneic cell manufacturing platform capable of producing multiple specialized cell types.

Publications

Patents

Pipeline